Boston Scientific Says PLATINUM Long Lesion Study Meets Primary Endpoint RTT News (BSX: News ) on Tuesday reported clinical endpoint data from its PLATINUM Long Lesion trial, demonstrating excellent outcomes for the PROMUS Element Everolimus-Eluting Platinum Chromium Stent System in patients with long coronary lesions. ... Boston Scientific's PROMUS Element(TM) Platinum Chromium Stent Demonstrates ... Boston Scientific reports positive data with new stent BOSTON SCIENTIFIC CORPORATION : Boston Scientific's PROMUS Element(TM ... |
